Scientific deep-dive

Does Weight Loss Fake Kidney Numbers?

Estimated kidney function is calculated from creatinine, and creatinine comes from muscle, so weight loss could flatter the number. A trial checked the estimates against a directly measured filtration rate.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

There is a mechanical reason to distrust kidney numbers taken during rapid weight loss. The standard estimate of kidney function is calculated from creatinine, and creatinine comes from muscle. Lose muscle, produce less creatinine, and the estimate improves while the kidney does exactly what it was doing before. A trial checked this against a directly measured filtration rate and found the worry does not materialize at around 10% weight loss.[1]

Why the question exists

Estimated GFR is not a measurement. It is a formula fed a blood marker, and the usual marker is creatinine, a waste product of muscle metabolism. The formula assumes your creatinine production is roughly what a person of your age and sex produces. Someone shedding lean mass breaks that assumption in a specific direction: less muscle, less creatinine, an eGFR that reads higher than the truth.

Cystatin C is the usual alternative because it is not muscle-derived, but it has its own sensitivity to fat mass and inflammation. So both estimates could plausibly drift during weight loss, in different directions, for different reasons.

How the trial answered it

SMART randomized 101 adults with chronic kidney disease and overweight or obesity, without type 2 diabetes, to 24 weeks of semaglutide 2.4 mg weekly or placebo. The design point is what it measured alongside the estimates: iohexol clearance, a direct measurement of filtration rather than a calculation from it. Body composition came from bioimpedance spectroscopy.

SMART, semaglutide against placebo at 24 weeks. Every figure is a between-group difference with its 95% confidence interval.[1]
MeasureDifference vs placebo95% CI
Total body weight−9.1 kg−11.0 to −7.2
Lean body mass−2.5 kg−6.6 to 1.6
Fat mass−3.9 kg−7.8 to 0.0
Extracellular water−0.9 L−1.6 to −0.1
Systolic blood pressure−6.3 mm Hg−10.9 to −1.7

Changes in weight, lean mass and fat mass showed no correlation with any GFR measure: the creatinine-based estimate, the cystatin C-based estimate, or the measured value. All Spearman coefficients came in below 0.23, and multivariable adjustment did not change it. The authors conclude that weight reductions of 10% with semaglutide do not influence GFR estimates.

Read the confidence intervals on that table

The paper’s own summary says semaglutide reduced lean body mass and fat mass. Look at the intervals for those two rows. Lean mass runs from −6.6 to +1.6. Fat mass runs from −7.8 to 0.0. Both include no difference. Total body weight, at −11.0 to −7.2, does not. So the scale moved decisively and the breakdown of what moved did not reach significance in 101 people.

That comes down to statistical power. A hundred-person trial is small for splitting a weight change into components with a technique as noisy as bioimpedance. The point estimates are still the best available, and their direction agrees with the larger body of work we have covered in lean mass on a drug versus dieting. But a reader told flatly that lean mass fell is owed the interval that goes with it.

The table also fails to add up: −2.5 kg of lean and −3.9 kg of fat comes to −6.4 kg, against a scale change of −9.1 kg. Bioimpedance is not a mass balance and its components are not obliged to sum to the scale. Each was estimated separately, with a wide interval of its own, so the gap reflects the limits of the measurement.

The blood pressure finding is separate and interesting

Systolic pressure fell 6.3 mm Hg more than placebo, and that fall correlated with the loss of extracellular water (Spearman 0.40, P = 0.005). It is the one correlation in the study that held.

The implication is that at least part of the blood pressure benefit here is fluid rather than weight. That matters in a kidney population, where fluid status is already something clinicians manage, and it is a different pathway from the one people assume when they credit blood pressure improvement to having lost weight.

What this does not establish

  • It is bounded at about 10%. The conclusion names that figure. Someone losing 20% or more is outside what this trial tested.
  • It is 24 weeks. Whether estimates stay accurate over years of treatment is not addressed.
  • It is not a safety finding. Whether these drugs help or harm kidneys is a different question with its own evidence (see GLP-1s and your kidneys).
  • Everyone in it already had CKD and none had type 2 diabetes. That is an unusual population, chosen deliberately, and not the average person on one of these drugs. Transplant recipients were not in it either, so it cannot say whether the eGFR gains reported after a kidney transplant are partly a creatinine effect.

Frequently Asked Questions

It is a reasonable worry because estimated GFR is calculated from creatinine, which comes from muscle. In a trial that checked estimates against a directly measured filtration rate, changes in weight, lean mass and fat mass showed no correlation with any GFR measure at around 10% weight loss.
SMART measured GFR by iohexol clearance (a direct measurement rather than a formula) alongside creatinine and cystatin C estimates, in 101 adults with chronic kidney disease and overweight or obesity over 24 weeks.
The trial's conclusion is explicitly bounded at reductions of 10%. Larger losses were not tested, and the mechanism that would cause distortion does not disappear at a threshold.
The point estimate was −2.5 kg of lean mass, but the 95% confidence interval ran from −6.6 to +1.6, which includes no difference. The trial was too small to settle the breakdown of the weight change, even though the total weight loss was clearly significant.
Systolic pressure dropped 6.3 mm Hg more than placebo, and that fall correlated with the loss of extracellular water rather than with weight. That points to fluid as part of the mechanism, which is a different route from the one usually assumed.

References

  1. 1.Heerspink HJL, Soler M, Beernink JM, et al. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial Clinical Journal of the American Society of Nephrology. 2026. PMID: 42308057.

Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show

GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.

11 min read

Tirzepatide vs Dulaglutide: A Real Head-to-Head

13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.

6 min read

Where the Evidence Is Strongest

Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.

7 min read

GLP-1s After a Kidney Transplant

A meta-analysis of 54,680 transplant recipients reports mortality nearly halved and kidney function improving. Four studies stand behind the mortality figure, and the size of the benefit is the reason to be careful with it.

6 min read

How Many People to Treat to Help One

Trials report benefit as a percentage, which sounds impressive and tells you nothing about your own odds. FLOW published the number needed to treat instead: 22, 13 and 17 over three years.

7 min read

Jardiance or Farxiga With Ozempic or Mounjaro: Taking an SGLT2 and a GLP-1

SGLT2 inhibitors like Jardiance and Farxiga are routinely taken with Ozempic or Mounjaro, and no label forbids it. Sugar and weight effects add up in trials; heart and kidney gains rest on subgroups. The real overlap is dehydration and ketoacidosis.

12 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.1

Direct Meds

Compounded semaglutide at $249/month

8.2

HealthRX

Compounded semaglutide at $165/month after a $99 first month

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →